Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00123604|
Recruitment Status : Completed
First Posted : July 25, 2005
Results First Posted : November 18, 2014
Last Update Posted : November 18, 2014
|Condition or disease||Intervention/treatment||Phase|
|Hypertension Type 2 Diabetes Mellitus||Drug: Carvedilol Drug: Metoprolol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effects of Carvedilol and Metoprolol on Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||June 2006|
|Actual Study Completion Date :||June 2006|
Carvedilol, orally, 25 mg, twice daily for five months
25 mg twice daily for five months.
Other Name: Coreg
Active Comparator: Metoprolol
Metoprolol, orally, 200 mg, twice daily for five months.
200 mg twice daily for five months.
Other Name: Lopressor
- Flow Mediated Dilation [ Time Frame: change from baseline to 5 months ]Flow mediated dilation is a measure of endothelial function. It is measured by the percent change in artery diameter (i.e. dilation), pre and post manual artery occlusion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00123604
|United States, Minnesota|
|St. Paul Heart Clinic|
|St. Paul, Minnesota, United States, 55102|
|Principal Investigator:||Alan J Bank, M.D.||St. Paul Heart Clinic|